FDA Clearance, First Device Implants, Clinical Trials, and First Quarter Financial Results - Analyst Notes on Intuitive Surgical, Medtronic, Stryker, Abbott and Boston Scientific

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, April 28, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Intuitive Surgical, Inc. (NASDAQ: ISRG), Medtronic, Inc. (NYSE: MDT), Stryker Corporation (NYSE: SYK), Abbott Laboratories (NYSE: ABT) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1662-100free.

Intuitive Surgical, Inc. Analyst Notes
On April 22, 2014, Intuitive Surgical, Inc. (Intuitive Surgical) announced that it has received FDA 510(k) clearance for the da Vinci Sp Surgical System, designed to expand the Company's single-incision product offering. The Company notified that the initial clearance is specific to urologic surgical procedures that are appropriate for a single port approach. Further, Intuitive Surgical also stated that the da Vinci Sp technology is not intended to be commercialized until the current technology is engineered to be fully compatible with the newly released da Vinci Xi™ Surgical System, which is currently projected for H2 2015. The full analyst notes on Intuitive Surgical are available to download free of charge at:


Medtronic, Inc. Analyst Notes
On April 22, 2014, Medtronic, Inc. (Medtronic) announced the first US implant of the Evera MRI™ SureScan® implantable cardioverter-defibrillator (ICD) System, following the FDA approval for its Investigational Device Exemption (IDE) application and pivotal clinical trial protocol. According to Medtronic, the product, which is presently available only for investigational use in the US, is the first ICD system to be evaluated in the US that allows for MRI scans positioned on any region of the body. "Our goal with the Evera MRI system is to give patients the most unrestricted access to MRI scans, and ultimately allow them to get the diagnostic answers they need," said Marshall Stanton, M.D., Vice President and General Manager of the Tachycardia business at Medtronic. "Medtronic has been a leader in developing implantable devices that are safe for the MRI environment, and we believe ICDs will be no exception in the near future." The full analyst notes on Medtronic are available to download free of charge at:


Stryker Corporation Analyst Notes
On April 23, 2014, Stryker Corporation (Stryker) reported Q1 2014 financial results. In Q1 2014, the Company's net sales increased 5.3% YoY to $2.3 billion. Q1 2014 net earnings were $70 million, or $0.18 per diluted share, compared to $304 million, or $0.79 per diluted share, in Q1 2013. "The strength of our diversified model was once again demonstrated in the first quarter with solid organic growth of 5%. Our continued investments in internal innovation, coupled with our recent acquisitions, position us well to meet our customers' evolving needs," said Kevin A. Lobo, President and CEO of Stryker. The full analyst notes on Stryker are available to download free of charge at:


Abbott Laboratories Analyst Notes
On April 16, 2014, Abbott Laboratories (Abbott) reported Q1 2014 financial results. The Company reported net sales of $5.2 billion for the quarter, down 2.5% YoY. Q1 2014 net earnings were $375 million, or $0.24 per diluted common share, compared with $544 million, or $0.34 per diluted common share, in Q1 2013. "We are off to a good start, and we continue to expect accelerating performance beginning in the second quarter as we target another year of double-digit ongoing earnings-per-share growth," said Miles D. White, Chairman and CEO of Abbott. The full analyst notes on Abbott are available to download free of charge at:


Boston Scientific Corporation Analyst Notes
On April 22, 2014, Boston Scientific Corporation (Boston Scientific) reported that it has conducted the first implant in the clinical trial of the next generation ACUITY™ X4 left-ventricular (LV) pacing leads and RELIANCE™ 4-FRONT defibrillation (ICD) leads. "The ACUITY X4 and RELIANCE 4-FRONT leads are designed to continue this tradition and will provide physicians better options to improve patient care," said Kenneth Stein, M.D., Senior Vice President and Chief Medical Officer of Rhythm Management at Boston Scientific. The Company notified that the ACUITY X$ left ventricular pacing leads and RELIANCE 4-FRONT defibrillator leads are CE Marked and are investigational devices, not available for sale in the US. The full analyst notes on Boston Scientific are available to download free of charge at:


About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review